Member Login

Forgot your password?

Let's Stay Connected

Find us on the popular social networks

LinkedIn

PharmTalk

JPET Highlight: Spleen Tyrosine Kinase Selective Inhibitor and Treatment of Rheumatoid Arthritis

 Permanent link

Spleen tyrosine kinase (Syk) is broadly involved in regulating leukocyte immune function, principally by facilitating cellular activation in response to receptor engagement of antigen or of immune complex. Coffey et al. report on the discovery and characterization of (4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R, 2S)-2-aminocyclohexylamino) pyrimidine-5-carboxamide acetate (P505-15), a novel, highly specific and potent orally available small-molecule inhibitor of Syk; they test the hypothesis that specific pharmacological inhibition of Syk kinase activity is sufficient to modulate leukocyte immune function and ameliorate inflammation in vivo. P505-15 potently and specifically inhibited Syk kinase activity in vitro (including whole blood assays), and ex vivo after oral dosing of P505-15, without inhibiting Syk-independent signaling. Submicromolar concentrations in blood, predicted to result in 67% inhibition of Syk, led to statistically significant anti-inflammatory effects in the mouse collagen antibody-induced arthritis (CAIA) and the rat collagen-induced arthritis (CIA) models. Syk kinase inhibition by P505-15 mimics the immunomodulatory phenotype of Syk knockout observed in other rodent models of rheumatoid arthritis. These data suggest that the specific inhibition of Syk may be a sufficient and safe strategy to control immune function in inflammatory diseases. P505-15 is currently in clinical development for the treatment of inflammatory diseases.

See article at J Pharmacol Exp Ther 2012, 340:350–359.

JPET Highlight: Knockin of Mutated α1 Glycine Receptor Subunits Alters Sensitivity to GABAergic Drugs

 Permanent link

Alcohol actions on recombinant glycine receptors (GlyRs) showed that mutations M287L and Q266I of the α1 subunit lead to a reduction in ethanol potentiation of glycine-induced current. Blednov et al. constructed knockin mice with each of these mutations, allowing the use of behavioral testing to determine the influence of these changes on behavioral effects of ethanol and other drugs. Rotarod ataxia was one behavioral effect of ethanol reduced more in the Q266I mutant than the M287L mutant. Mutant mice also differed in ethanol consumption, ethanol-stimulated startle response, signs of acute physical dependence, and duration of loss of righting response produced by ethanol, butanol, ketamine, pentobarbital, and flurazepam. Some of these behavioral changes were mimicked in wild-type mice by acute injections of low, subconvulsive doses of strychnine. Both mutants showed increased acoustic startle response and increased sensitivity to strychnine seizures. In addition to reducing ethanol action on the GlyRs, these mutations reduced glycinergic inhibition, which may also alter sensitivity to GABAergic drugs. These results show the ability of a single amino acid change in the GlyR α1 subunit to decrease specific behavioral actions of ethanol and to alter other nonethanol behaviors, demonstrating the importance of GlyR function in diverse neuronal systems.

See article at J Pharmacol Exp Ther 2012, 340:317–329.

Become a Member

Join over 4,500 members enjoying ASPET publications, discounts on registration for Experimental Biology, networking opportunities, and much more.  Apply Today!

What is Pharmacology?

Pharmacology is the science of drug action on biological systems. In its entirety, pharmacology embraces knowledge of the sources, chemical properties, biological effects and therapeutic uses of drugs. Learn more!